We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.
- Authors
Mengual, Lourdes; Frantzi, Maria; Mokou, Marika; Ingelmo-Torres, Mercedes; Vlaming, Michiel; Merseburger, Axel S.; Roesch, Marie C.; Culig, Zoran; Alcaraz, Antonio; Vlahou, Antonia; Mischak, Harald; Van der Heijden, Antoine G.
- Abstract
<bold>Background: </bold>Non-invasive urine-based biomarkers can potentially improve current diagnostic and monitoring protocols for bladder cancer (BC). Here we assess the performance of earlier published biomarker panels for BC detection (BC-116) and monitoring of recurrence (BC-106) in combination with cytology, in two prospectively collected patient cohorts.<bold>Methods: </bold>Of the 602 patients screened for BC, 551 were found eligible. For the primary setting, 73 patients diagnosed with primary BC (n = 27) and benign urological disorders, including patients with macroscopic haematuria, cystitis and/or nephrolithiasis (n = 46) were included. In total, 478 patients under surveillance were additionally considered (83 BC recurrences; 395 negative for recurrence). Urine samples were analysed with capillary electrophoresis-mass spectrometry. The biomarker score was estimated via support vector machine-based software.<bold>Results: </bold>Validation of BC-116 biomarker panel resulted in 89% sensitivity and 67% specificity (AUCBC-116 = 0.82). A diagnostic score based on cytology and BC-116 resulted in good (AUCNom116 = 0.85) but not significantly better performance (P = 0.5672). A diagnostic score including BC-106 and cytology was evaluated (AUCNom106 = 0.82), significantly outperforming both cytology (AUCcyt = 0.72; P = 0.0022) and BC-106 (AUCBC-106 = 0.67; P = 0.0012).<bold>Conclusions: </bold>BC-116 biomarker panel is a useful test for detecting primary BC. BC-106 classifier integrated with cytology showing >95% negative predictive value, might be useful for decreasing the number of cystoscopies during surveillance.
- Subjects
BLADDER tumors; CANCER relapse; RESEARCH funding; ROUTINE diagnostic tests; LONGITUDINAL method; PEPTIDES; SENSITIVITY &; specificity (Statistics)
- Publication
British Journal of Cancer, 2022, Vol 127, Issue 11, p2043
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/s41416-022-01992-3